These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 16837489

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [Abstract] [Full Text] [Related]

  • 5. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [Abstract] [Full Text] [Related]

  • 6. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
    Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, Cohen SB, Gangnon RE, Schiff MH.
    J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
    Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA.
    J Rheumatol; 2004 Dec; 31(12):2356-9. PubMed ID: 15570634
    [Abstract] [Full Text] [Related]

  • 11. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
    [Abstract] [Full Text] [Related]

  • 18. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 19. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F.
    Arch Intern Med; 2006 Jan 09; 166(1):57-63. PubMed ID: 16401811
    [Abstract] [Full Text] [Related]

  • 20. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.
    van Vollenhoven RF, Klareskog L.
    Arthritis Rheum; 2003 Jun 09; 48(6):1500-3. PubMed ID: 12794816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.